(redirected from femoropopliteal)
fem-popfemoropopliteal (bypass surgery)
References in periodicals archive ?
Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany.
Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: Focus on the Zilver PTX drug-eluting peripheral stent.
Segmental distribution of Buerger disease showed involvement of femoropopliteal segment in 40% cases which was in agreement with the study by Suzuki et al.
The VIVA sponsored study is assessing outcomes for patients with significantly calcified and symptomatic femoropopliteal peripheral artery disease (PAD), following adjunctive use of directional atherectomy and drug-coated balloon (DCB).
In view of the active bleeding in the thigh, it was decided to perform a selective arteriography, which identified the source of bleeding in a branch of the superficial femoral artery near the femoropopliteal junction.
The approval gave the company a strong position as it is, according to Bard, the first and only FDA-approved drug coated balloon available in the United States for the treatment of femoropopliteal occlusive disease.
According to Bard, the Lutonix 035 DCB is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease in the femoropopliteal arteries.
Prevalence and clinical impact of stent fractures after femoropopliteal stenting.
The report provides in-depth insight into the use of DEB for coronary and peripheral applications in the lower extremity including in-stent restenosis, bifurcation lesions, small vessel disease, femoropopliteal artery and below-the-knee lesions, chronic total occlusions, acute myocardial infarction and lesions in diabetics.
Cryoplasty for the treatment of femoropopliteal arterial disease: Results of a prospective, multicenter registry.
The drug was particularly effective in patients who had femoropopliteal disease, increasing maximal walking time to 286 seconds, compared with patients who had aortoiliac disease, whose maximal walking time improved by 127 seconds.